Cerebral Malaria and Neuronal Implications of Plasmodium Falciparum Infection: From Mechanisms to Advanced Models
Source abstract
Abstract
Abstract Reorganization of host red blood cells by the malaria parasite Plasmodium falciparum enables their sequestration via attachment to the microvasculature. This artificially increases the dwelling time of the infected red blood cells within inner organs such as the brain, which can lead to cerebral malaria. Cerebral malaria is the deadliest complication patients infected with P. falciparum can experience and still remains a major public health concern despite effective antimalarial therapies. Here, the current understanding of the effect of P. falciparum cytoadherence and their secreted proteins on structural features of the human blood‐brain barrier and their involvement in the pathogenesis of cerebral malaria are highlighted. Advanced 2D and 3D in vitro models are further assessed to study this devastating interaction between parasite and host. A better understanding of the molecular mechanisms leading to neuronal and cognitive deficits in cerebral malaria will be pivotal in devising new strategies to treat and prevent blood‐brain barrier dysfunction and subsequent neurological damage in patients with cerebral malaria.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Malaria Research and Control · Drug Transport and Resistance Mechanisms · Mosquito-borne diseases and control
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Internal Medicine Section of Infectious Diseases Yale University School of Medicine 300 Cedar Street New Haven CT 06510 USA
Centre for Infectious Diseases, Parasitology Heidelberg University Hospital Im Neuenheimer Feld 324 69120 Heidelberg Germany
Department of Physiology Anatomy and Genetics University of Oxford Oxford OX1 3QU UK
Kavli Institute for NanoScience Discovery University of Oxford Oxford UK
Oxford Parkinson's Disease Centre University of Oxford Oxford UK
Funding
Leverhulme Trust
References (100+)
Show source-provided references
1. 10.1161/01.RES.83.4.35310.1161/01.RES.83.4.353 ↗
2. 10.1155/S096293519400020710.1155/S0962935194000207 ↗
3. 10.1097/01.LAB.0000017372.76297.EB10.1097/01.LAB.0000017372.76297.EB ↗
4. 10.1172/JCI8730610.1172/JCI87306 ↗
5. 10.1371/journal.pone.013819110.1371/journal.pone.0138191 ↗
6. 10.1093/cvr/cvu01510.1093/cvr/cvu015 ↗
7. Essien E. M. · Afr. J. Med. Med. Sci. · 2014 · 43 · 287
8. 10.7150/ijbs.750210.7150/ijbs.7502 ↗
9. 10.1056/NEJMoa140011610.1056/NEJMoa1400116 ↗
10. 10.1086/50507810.1086/505078 ↗
11. 10.4269/ajtmh.17-030910.4269/ajtmh.17-0309 ↗
12. 10.1002/bies.20190013810.1002/bies.201900138 ↗
13. 10.4269/ajtmh.1997.56.58510.4269/ajtmh.1997.56.585 ↗
14. 10.1007/978-3-7091-6837-0_3510.1007/978-3-7091-6837-0_35 ↗
15. 10.1038/s41598-022-09748-y10.1038/s41598-022-09748-y ↗
16. 10.1016/j.pt.2019.04.01010.1016/j.pt.2019.04.010 ↗
17. 10.1177/0271678X1561717210.1177/0271678X15617172 ↗
18. 10.1038/nchembio.7010.1038/nchembio.70 ↗
19. 10.1016/j.cell.2007.10.04910.1016/j.cell.2007.10.049 ↗
20. 10.1126/science.117108510.1126/science.1171085 ↗
21. 10.1038/nm158610.1038/nm1586 ↗
22. 10.1016/j.biocel.2008.09.02010.1016/j.biocel.2008.09.020 ↗
23. Lum H. · Am. J. Physiol. · 1994 · 267 · L223
24. 10.4161/viru.2594910.4161/viru.25949 ↗
25. 10.1017/S003118200007568510.1017/S0031182000075685 ↗
26. 10.1186/1475-2875-8-11310.1186/1475-2875-8-113 ↗
27. 10.15252/emmm.20180990310.15252/emmm.201809903 ↗
28. 10.1111/febs.1409710.1111/febs.14097 ↗
29. 10.1046/j.0305-1846.2001.00360.x10.1046/j.0305-1846.2001.00360.x ↗
30. 10.1086/50854710.1086/508547 ↗
31. 10.1007/s12223-013-0239-510.1007/s12223-013-0239-5 ↗
32. 10.1182/blood-2009-07-23515010.1182/blood-2009-07-235150 ↗
33. 10.1111/jth.1216010.1111/jth.12160 ↗
34. 10.1161/ATVBAHA.115.30696410.1161/ATVBAHA.115.306964 ↗
35. 10.1089/ars.2007.200710.1089/ars.2007.2007 ↗
36. 10.1111/jth.1240110.1111/jth.12401 ↗
37. 10.1152/ajpcell.2001.280.4.C71910.1152/ajpcell.2001.280.4.C719 ↗
38. 10.1016/S0002-9440(10)64885-710.1016/S0002-9440(10)64885-7 ↗
39. 10.1093/brain/awg06110.1093/brain/awg061 ↗
40. 10.2174/1567202611310999000310.2174/15672026113109990003 ↗
41. 10.1016/j.lfs.2012.07.00610.1016/j.lfs.2012.07.006 ↗
42. 10.1016/S0165-5728(00)00187-910.1016/S0165-5728(00)00187-9 ↗
43. 10.1182/blood-2015-11-63646410.1182/blood-2015-11-636464 ↗
44. 10.1080/17474086.2016.117957110.1080/17474086.2016.1179571 ↗
45. 10.1016/j.ijpara.2016.08.00210.1016/j.ijpara.2016.08.002 ↗
46. 10.1016/0166-6851(93)90069-A10.1016/0166-6851(93)90069-A ↗
47. 10.1128/IAI.73.8.4941-4947.200510.1128/IAI.73.8.4941-4947.2005 ↗
48. 10.1093/infdis/jir05810.1093/infdis/jir058 ↗
49. 10.1016/j.atherosclerosis.2014.09.00110.1016/j.atherosclerosis.2014.09.001 ↗
50. 10.1089/ars.2016.695410.1089/ars.2016.6954 ↗
51. 10.1016/S0021-9258(20)64313-710.1016/S0021-9258(20)64313-7 ↗
52. 10.1016/0003-9861(91)90224-710.1016/0003-9861(91)90224-7 ↗
53. 10.1016/S0021-9258(17)36703-010.1016/S0021-9258(17)36703-0 ↗
54. 10.1161/ATVBAHA.112.30106810.1161/ATVBAHA.112.301068 ↗
55. 10.1161/01.CIR.0000012748.58444.0810.1161/01.CIR.0000012748.58444.08 ↗
56. 10.1016/0169-4758(91)90142-B10.1016/0169-4758(91)90142-B ↗
57. 10.1186/1475-2875-12-26010.1186/1475-2875-12-260 ↗
58. 10.1182/blood-2009-06-22641510.1182/blood-2009-06-226415 ↗
59. 10.1016/j.freeradbiomed.2013.07.00310.1016/j.freeradbiomed.2013.07.003 ↗
60. 10.1016/j.arr.2008.07.00210.1016/j.arr.2008.07.002 ↗
61. 10.1111/ejn.1372310.1111/ejn.13723 ↗
62. 10.1126/science.787846410.1126/science.7878464 ↗
63. 10.1089/ars.2012.514910.1089/ars.2012.5149 ↗
64. 10.3390/cells1101007210.3390/cells11010072 ↗
65. 10.1002/(SICI)1098-1136(199601)16:1<51::AID-GLIA6>3.0.CO;2-E10.1002/(SICI)1098-1136(199601)16:1<51::AID-GLIA6>3.0.CO;2-E ↗
66. Medana I. M. · Am. J. Pathol. · 1997 · 150 · 1473
67. 10.1002/(SICI)1098-1136(199702)19:2<91::AID-GLIA1>3.0.CO;2-C10.1002/(SICI)1098-1136(199702)19:2<91::AID-GLIA1>3.0.CO;2-C ↗
68. Deininger M. H. · Eur. Cytokine Network · 2002 · 13 · 173
69. 10.1086/36796010.1086/367960 ↗
70. 10.1111/j.1538-7836.2006.02232.x10.1111/j.1538-7836.2006.02232.x ↗
71. 10.1016/j.pt.2008.03.00910.1016/j.pt.2008.03.009 ↗
72. 10.1080/1073968070145151610.1080/10739680701451516 ↗
73. 10.1186/2045-8118-11-110.1186/2045-8118-11-1 ↗
74. 10.3389/fimmu.2018.0310010.3389/fimmu.2018.03100 ↗
75. 10.1159/00051555710.1159/000515557 ↗
76. 10.1186/1475-2875-8-29510.1186/1475-2875-8-295 ↗
77. 10.1186/1475-2875-12-5010.1186/1475-2875-12-50 ↗
78. 10.4049/jimmunol.176.2.118010.4049/jimmunol.176.2.1180 ↗
79. 10.1182/blood-2005-04-153010.1182/blood-2005-04-1530 ↗
80. 10.1182/blood-2003-10-368510.1182/blood-2003-10-3685 ↗
81. 10.1093/femsre/fuv04610.1093/femsre/fuv046 ↗
82. 10.3390/ijms2023600810.3390/ijms20236008 ↗
83. 10.3390/pharmaceutics1311177910.3390/pharmaceutics13111779 ↗
84. Machado F. S. · Exp. Biol. Med. · 2006 · 231 · 1176
85. 10.1016/0304-3940(93)90432-K10.1016/0304-3940(93)90432-K ↗
86. 10.1007/978-1-4615-2920-0_3710.1007/978-1-4615-2920-0_37 ↗
87. 10.1146/annurev.pathol.2.010506.09191310.1146/annurev.pathol.2.010506.091913 ↗
88. 10.1111/j.1462-5822.2010.01528.x10.1111/j.1462-5822.2010.01528.x ↗
89. 10.1161/CIRCRESAHA.117.31079510.1161/CIRCRESAHA.117.310795 ↗
90. 10.1182/blood-2012-09-45555010.1182/blood-2012-09-455550 ↗
91. 10.3389/fimmu.2018.0271210.3389/fimmu.2018.02712 ↗
92. 10.1182/blood-2013-11-46243210.1182/blood-2013-11-462432 ↗
93. 10.1128/IAI.74.1.645-653.200610.1128/IAI.74.1.645-653.2006 ↗
94. 10.1016/j.ijpara.2006.02.00510.1016/j.ijpara.2006.02.005 ↗
95. 10.1371/journal.pone.001965110.1371/journal.pone.0019651 ↗
96. 10.1007/s00018-009-0211-310.1007/s00018-009-0211-3 ↗
97. 10.1155/2015/16893710.1155/2015/168937 ↗
98. 10.1111/j.1365-2141.1994.tb04877.x10.1111/j.1365-2141.1994.tb04877.x ↗
99. 10.1086/51984410.1086/519844 ↗
100. 10.1016/j.ajpath.2011.09.03810.1016/j.ajpath.2011.09.038 ↗